AstraZeneca (AZN) Stock Rating Reaffirmed by BMO Capital Markets
BMO Capital Markets reissued their outperform rating on shares of AstraZeneca (NYSE:AZN) in a research note published on Monday, The Fly reports. BMO Capital Markets currently has a $48.00 price objective on the stock.
Other research analysts have also issued research reports about the stock. Deutsche Bank reiterated a buy rating on shares of AstraZeneca in a report on Monday, November 12th. ValuEngine upgraded shares of AstraZeneca from a hold rating to a buy rating in a report on Saturday, July 28th. Zacks Investment Research upgraded shares of AstraZeneca from a hold rating to a buy rating and set a $44.00 price objective for the company in a report on Tuesday, October 9th. Guggenheim assumed coverage on shares of AstraZeneca in a report on Monday, October 8th. They issued a buy rating for the company. Finally, Investec downgraded shares of AstraZeneca from a buy rating to a hold rating in a research report on Monday. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $41.74.
Shares of NYSE AZN opened at $40.80 on Monday. The company has a market capitalization of $103.01 billion, a P/E ratio of 9.53, a price-to-earnings-growth ratio of 2.09 and a beta of 0.57. AstraZeneca has a 1 year low of $31.99 and a 1 year high of $41.78. The company has a debt-to-equity ratio of 1.36, a current ratio of 0.86 and a quick ratio of 0.66.
In related news, major shareholder Plc Astrazeneca acquired 246,666 shares of AstraZeneca stock in a transaction dated Friday, September 28th. The stock was bought at an average price of $15.00 per share, with a total value of $3,699,990.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Several hedge funds have recently made changes to their positions in AZN. Factorial Partners LLC acquired a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $119,000. Bessemer Group Inc. grew its position in AstraZeneca by 64.3% in the 2nd quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock valued at $163,000 after purchasing an additional 1,820 shares during the period. NEXT Financial Group Inc acquired a new stake in AstraZeneca in the 3rd quarter valued at $169,000. Tiverton Asset Management LLC bought a new position in AstraZeneca during the 2nd quarter valued at $178,000. Finally, Gilman Hill Asset Management LLC bought a new position in AstraZeneca during the 2nd quarter valued at $205,000. 17.38% of the stock is owned by institutional investors.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What is a Reverse Stock Split?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.